Skip to main content
. Author manuscript; available in PMC: 2013 Aug 20.
Published in final edited form as: J Control Release. 2012 Jun 15;162(1):102–110. doi: 10.1016/j.jconrel.2012.06.008

Figure 6.

Figure 6

Animals receiving three separate doses of 14:1 formulation si-UL29 NPs showed reduced HSV-2 symptoms and extended survival relative to mice receiving two doses (−2 hr and 4 hr relative to infection) of either NPs, lipoplexes (OLF), or medium alone. Both NP treatment groups (2 or 3 treatments) resulted in extended survival relative to lipoplexes. (A) Percent survival of mice and (B) disease assessment score with respect to time. Disease severity and progression were evaluated daily according to a five point scale: 0, no signs of infection; 1, slight genital erythema and edema; 2, moderate genital inflammation; 3, purulent genital lesions; 4, hind limb paralysis; 5, death. Error bars represent standard error of the mean.